Mergers & Acquisitions ·
Supernus stockholders approve $4.7B merger with Indivior
SUPNSupernus, Inc.
Supernus Pharmaceuticals, Inc. held a special meeting of its stockholders on October 15, 2026, to vote on the proposed Merger Agreement with Indivior Pharmaceuticals Inc. The proposal to adopt the Merger Agreement was approved by 48,249,532 votes in favor, compared to 235,601 against and 67,004 abstentions. A separate non-binding advisory vote on executive compensation related to the transaction received 32,688,410 votes for and 15,847,350 against. The merger involves Merger Sub merging with Supernus, which will continue as a wholly-owned subsidiary of Indivior. Supernus Pharmaceuticals operates in the pharmaceutical industry.